Jennifer L Miller, M.D.
Professor
About Jennifer L Miller
Hi my name is Dr. Jennifer Miller and I am a Professor in the division of pediatric endocrinology. I graduated with my M.D. from the University of Florida in 1998, and my M.S. in Clinical Investigation from the University of Florida in 2005. I have done all of my training in pediatrics and pediatric endocrinology at the University of Florida. I specialize in the care and treatment of individuals with Prader-Willi syndrome and other genetic causes of early-onset excessive weight gain. Go gators!
Accomplishments
Castle Connolly Regional Top Doctors
2018
·
peer nomination, extensive research and careful review and screening by our doctor-directed research team
Customeer Service Key Award
2017
·
Shands Hospital
Customer Service Key Award
2016
·
Shands Hospital
Patient's Choice Award
2014-2018
·
National Award
Compassionate Doctor Award
2011-2018
·
National Award
Teaching Profile
Courses Taught
2018
MDC7400 Pediatric Clerkship
2023
BMS6751 Nutrition and Health
Clinical Profile
Specialties
- Pediatrics
Subspecialties
- Pediatric Endocrinology
Areas of Interest
- Diabetes
- High blood pressure – children
- Obesity in children
- Pediatric pituitary and skull base services
- Prader-Willi syndrome
Research Profile
My research focuses on investigation of the etiology and possible treatment for obesity and metabolic abnormalities in individuals with Prader-Willi syndrome and early-onset obesity. I have been working towards achieving an appropriate treatment for hyperphagia for the past 12 years. I currently follow over 500 patients with Prader-Willi syndrome from around the world, and over 100 patients with early-onset obesity due to other genetic causes. I am working on clinical treatment trials to treat hyperphagia in individuals with Prader-Willi syndrome and early-onset obesity..
Open Researcher and Contributor ID (ORCID)
0000-0003-4370-3438
Publications
2024
Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
Journal of neurodevelopmental disorders.
16(1)
[DOI] 10.1186/s11689-024-09536-x.
[PMID] 38671361.
2024
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study.
Obesity (Silver Spring, Md.).
32(2):252-261
[DOI] 10.1002/oby.23928.
[PMID] 37919617.
2024
Neuromodulation for the treatment of Prader-Willi syndrome – A systematic review.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
21(3)
[DOI] 10.1016/j.neurot.2024.e00339.
[PMID] 38430811.
2023
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial
The Journal of Clinical Endocrinology & Metabolism.
108(7):1676-1685
[DOI] 10.1210/clinem/dgad014.
[PMID] 36639249.
2023
Hyperinsulinemia is a probable trigger for weight gain and hyperphagia in individuals with Prader-Willi syndrome.
Obesity science & practice.
9(4):383-394
[DOI] 10.1002/osp4.663.
[PMID] 37546289.
2023
Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
The Journal of clinical endocrinology and metabolism.
108(7):1696-1708
[DOI] 10.1210/clinem/dgad015.
[PMID] 36633570.
2023
The Arduous Path to Drug Approval for the Management of Prader-Willi Syndrome: A Historical Perspective and Call to Action.
International journal of molecular sciences.
24(14)
[DOI] 10.3390/ijms241411574.
[PMID] 37511333.
2022
Critical review of bariatric surgical outcomes in patients with Prader-Willi syndrome and other hyperphagic disorders.
Obesity (Silver Spring, Md.).
30(5):973-981
[DOI] 10.1002/oby.23385.
[PMID] 35416416.
2022
Molecular Classes and Growth Hormone Treatment Effects on Behavior and Emotion in Patients with Prader-Willi Syndrome.
Journal of clinical medicine.
11(9)
[DOI] 10.3390/jcm11092572.
[PMID] 35566699.
2022
The Efficacy, Safety, and Pharmacology of a Ghrelin O-Acyltransferase Inhibitor for the Treatment of Prader-Willi Syndrome.
The Journal of clinical endocrinology and metabolism.
107(6):e2373-e2380
[DOI] 10.1210/clinem/dgac105.
[PMID] 35213714.
2022
Thrombosis Risk History and D-dimer Levels in Asymptomatic Individuals with Prader-Willi Syndrome.
Journal of clinical medicine.
11(7)
[DOI] 10.3390/jcm11072040.
[PMID] 35407648.
2021
Adults with Prader-Willi syndrome exhibit a unique microbiota profile.
BMC research notes.
14(1)
[DOI] 10.1186/s13104-021-05470-6.
[PMID] 33549146.
2021
Evaluating Sleep Disturbances in Children With Rare Genetic Neurodevelopmental Syndromes
Pediatric Neurology.
123:30-37
[DOI] 10.1016/j.pediatrneurol.2021.07.009.
[PMID] 34388423.
2021
Hypogonadism in Adult Males with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion.
Journal of clinical medicine.
10(19)
[DOI] 10.3390/jcm10194361.
[PMID] 34640379.
2021
Hypogonadism in Women with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion.
Journal of clinical medicine.
10(24)
[DOI] 10.3390/jcm10245781.
[PMID] 34945077.
2021
Incidence of strabismus, strabismus surgeries, and other vision conditions in Prader-Willi syndrome: data from the Global Prader-Willi Syndrome Registry.
BMC ophthalmology.
21(1)
[DOI] 10.1186/s12886-021-02057-4.
[PMID] 34380467.
2021
Influence of molecular classes and growth hormone treatment on growth and dysmorphology in Prader-Willi syndrome: A multicenter study.
Clinical genetics.
100(1):29-39
[DOI] 10.1111/cge.13947.
[PMID] 33615449.
2020
Dietary Management for Adolescents with Prader-Willi Syndrome.
Adolescent health, medicine and therapeutics.
11:113-118
[DOI] 10.2147/AHMT.S214893.
[PMID] 32922110.
2020
Microbiota profile and efficacy of probiotic supplementation on laxation in adults affected by Prader-Willi Syndrome: A randomized, double-blind, crossover trial.
Molecular genetics & genomic medicine.
8(12)
[DOI] 10.1002/mgg3.1535.
[PMID] 33103385.
2019
A multidisciplinary approach to the clinical management of Prader-Willi syndrome.
Molecular genetics & genomic medicine.
7(3)
[DOI] 10.1002/mgg3.514.
[PMID] 30697974.
2019
Birth seasonality studies in a large Prader-Willi syndrome cohort.
American journal of medical genetics. Part A.
179(8):1531-1534
[DOI] 10.1002/ajmg.a.61263.
[PMID] 31225937.
2019
Early Diagnosis in Prader-Willi Syndrome Reduces Obesity and Associated Co-Morbidities.
Genes.
10(11)
[DOI] 10.3390/genes10110898.
[PMID] 31698873.
2019
Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study.
Journal of medical genetics.
56(3):149-153
[DOI] 10.1136/jmedgenet-2018-105301.
[PMID] 29730598.
2019
Prader-Willi Syndrome – Clinical Genetics, Diagnosis and Treatment Approaches: An Update.
Current pediatric reviews.
15(4):207-244
[DOI] 10.2174/1573396315666190716120925.
[PMID] 31333129.
2018
Hormonal, metabolic and skeletal phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome.
Journal of medical genetics.
55(5):307-315
[DOI] 10.1136/jmedgenet-2017-105024.
[PMID] 29496979.
2018
Multicentre study of maternal and neonatal outcomes in individuals with Prader-Willi syndrome.
Journal of medical genetics.
55(9):594-598
[DOI] 10.1136/jmedgenet-2017-105118.
[PMID] 29776967.
2018
Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection.
The Journal of clinical endocrinology and metabolism.
103(2):370-375
[DOI] 10.1210/jc.2017-02080.
[PMID] 29220529.
2018
The effects of Bifidobacterium animalis ssp. lactis B94 on gastrointestinal wellness in adults with Prader-Willi syndrome: study protocol for a randomized controlled trial.
Trials.
19(1)
[DOI] 10.1186/s13063-018-2648-x.
[PMID] 29703235.
2017
Oxytocin treatment in children with Prader–Willi syndrome: A double‐blind, placebo‐controlled, crossover study
American Journal of Medical Genetics Part A.
173(5):1243-1250
[DOI] 10.1002/ajmg.a.38160.
[PMID] 28371242.
2016
Elevated plasma oxytocin levels in children with Prader-Willi syndrome compared with healthy unrelated siblings.
American journal of medical genetics. Part A.
170(3):594-601
[DOI] 10.1002/ajmg.a.37488.
[PMID] 26615966.
2016
Growth Charts for Prader-Willi Syndrome During Growth Hormone Treatment.
Clinical pediatrics.
55(10):957-74
[DOI] 10.1177/0009922815617973.
[PMID] 26842920.
2016
Higher plasma orexin a levels in children with Prader-Willi syndrome compared with healthy unrelated sibling controls.
American journal of medical genetics. Part A.
170(9):2328-33
[DOI] 10.1002/ajmg.a.37777.
[PMID] 27518917.
2016
Higher plasma orexin A levels in children with Prader-Willi syndrome compared with healthy unrelated sibling controls.
American journal of medical genetics. Part A.
170(8):2097-102
[DOI] 10.1002/ajmg.a.37749.
[PMID] 27214028.
2016
The High Direct Medical Costs of Prader-Willi Syndrome.
The Journal of pediatrics.
175:137-43
[DOI] 10.1016/j.jpeds.2016.05.018.
[PMID] 27283463.
2015
Growth charts for non-growth hormone treated Prader-Willi syndrome.
Pediatrics.
135(1):e126-35
[DOI] 10.1542/peds.2014-1711.
[PMID] 25489013.
2015
Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia.
American journal of medical genetics. Part A.
167A(1):69-79
[DOI] 10.1002/ajmg.a.36810.
[PMID] 25355237.
2015
Laparoscopic sleeve gastrectomy in 108 obese children and adolescents ages 5 to 21 years by Alqahtani AR, Antonisamy B, Alamri H, Elahmedi M, Zimmerman VA.
Annals of surgery.
261(4)
[DOI] 10.1097/SLA.0b013e3182a7187c.
[PMID] 24045441.
2015
Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome.
Diseases (Basel, Switzerland).
3(2):78-85
[DOI] 10.3390/diseases3020078.
[PMID] 28943610.
2015
The neurobiological drive for overeating implicated in Prader-Willi syndrome.
Brain research.
1620:72-80
[DOI] 10.1016/j.brainres.2015.05.008.
[PMID] 25998539.
2014
An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome.
American journal of medical genetics. Part A.
164A(2):421-4
[DOI] 10.1002/ajmg.a.36306.
[PMID] 24311388.
2014
Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study.
Journal of pediatric endocrinology & metabolism : JPEM.
27(1-2):23-9
[DOI] 10.1515/jpem-2013-0116.
[PMID] 23893676.
2014
Frequency of Prader-Willi syndrome in births conceived via assisted reproductive technology.
Genetics in medicine : official journal of the American College of Medical Genetics.
16(2):164-9
[DOI] 10.1038/gim.2013.97.
[PMID] 23928912.
2014
Hypoglycemia in Prader-Willi syndrome.
American journal of medical genetics. Part A.
164A(5):1127-9
[DOI] 10.1002/ajmg.a.36405.
[PMID] 24458695.
2014
Morbidity of total pancreatectomy with islet cell auto-transplantation compared to total pancreatectomy alone.
HPB : the official journal of the International Hepato Pancreato Biliary Association.
16(6):522-7
[DOI] 10.1111/hpb.12168.
[PMID] 23992021.
2014
Perioperative outcomes of pancreaticoduodenectomy compared to total pancreatectomy for neoplasia.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.
18(3):549-54
[DOI] 10.1007/s11605-013-2393-0.
[PMID] 24165872.
2013
Altered functional brain networks in Prader-Willi syndrome.
NMR in biomedicine.
26(6):622-9
[DOI] 10.1002/nbm.2900.
[PMID] 23335390.
2013
Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features.
The Journal of clinical investigation.
123(7):3037-41
[DOI] 10.1172/JCI68035.
[PMID] 23778136.
2013
Prader-Willi syndrome and sleep-disordered breathing.
Pediatric annals.
42(10):200-4
[DOI] 10.3928/00904481-20130924-10.
[PMID] 24126982.
2012
Approach to the child with prader-willi syndrome.
The Journal of clinical endocrinology and metabolism.
97(11):3837-44
[DOI] 10.1210/jc.2012-2543.
[PMID] 23129592.
2012
Letter to the editor: Long-term experience with duodenal switch in adolescents.
Obesity surgery.
22(3):517-8
[DOI] 10.1007/s11695-011-0502-2.
[PMID] 21874367.
2012
Prader-Willi syndrome.
Genetics in medicine : official journal of the American College of Medical Genetics.
14(1):10-26
[DOI] 10.1038/gim.0b013e31822bead0.
[PMID] 22237428.
2012
Unique and atypical deletions in Prader-Willi syndrome reveal distinct phenotypes.
European journal of human genetics : EJHG.
20(3):283-90
[DOI] 10.1038/ejhg.2011.187.
[PMID] 22045295.
2011
Carnitine and coenzyme Q10 levels in individuals with Prader-Willi syndrome.
American journal of medical genetics. Part A.
155A(3):569-73
[DOI] 10.1002/ajmg.a.33887.
[PMID] 21337696.
2011
Evidence of a mechanism for isodicentric chromosome Y formation in a 45,X/46,X,idic(Y)(p11.31)/46,X,del(Y)(p11.31) mosaic karyotype.
European journal of medical genetics.
54(2):161-4
[DOI] 10.1016/j.ejmg.2010.11.002.
[PMID] 21078420.
2011
Nutritional phases in Prader-Willi syndrome.
American journal of medical genetics. Part A.
155A(5):1040-9
[DOI] 10.1002/ajmg.a.33951.
[PMID] 21465655.
2009
“Efficacy of laparoscopic sleeve gastrectomy as a stand-alone technique for children with morbid obesity” and “BioEnterics intragastric balloon for treatment of morbid obesity in Prader-Willi syndrome: specific risks and benefits”.
Obesity surgery.
19(5):671-2; author reply 673
[DOI] 10.1007/s11695-008-9742-1.
[PMID] 18982398.
2009
Early childhood obesity is associated with compromised cerebellar development.
Developmental neuropsychology.
34(3):272-83
[DOI] 10.1080/87565640802530961.
[PMID] 19437203.
2009
Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.
5(5):448-53
[PMID] 19961030.
2008
Pituitary abnormalities in Prader-Willi syndrome and early onset morbid obesity.
American journal of medical genetics. Part A.
146A(5):570-7
[PMID] 17431897.
2008
Potency and fate specification in CNS stem cell populations in vitro.
Cell stem cell.
3(6):670-80
[DOI] 10.1016/j.stem.2008.09.012.
[PMID] 19041783.
2007
Enhanced activation of reward mediating prefrontal regions in response to food stimuli in Prader-Willi syndrome.
Journal of neurology, neurosurgery, and psychiatry.
78(6):615-9
[PMID] 17158560.
2007
Intracranial abnormalities detected by three-dimensional magnetic resonance imaging in Prader-Willi syndrome.
American journal of medical genetics. Part A.
143A(5):476-83
[PMID] 17103438.
2007
Management approaches for pediatric obesity.
Nature clinical practice. Endocrinology & metabolism.
3(12):810-8
[PMID] 18026159.
2007
Sylvian fissure morphology in Prader-Willi syndrome and early-onset morbid obesity.
Genetics in medicine : official journal of the American College of Medical Genetics.
9(8):536-43
[PMID] 17700392.
2006
Central hypothyroidism with oxcarbazepine therapy.
Pediatric neurology.
34(3):242-4
[PMID] 16504798.
2006
Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome.
The Journal of clinical endocrinology and metabolism.
91(2):413-7
[PMID] 16317059.
2006
The treatment of type 2 diabetes mellitus in youth : which therapies?
Treatments in endocrinology.
5(4):201-10
[PMID] 16878999.
2005
The management of type 2 diabetes mellitus in children and adolescents.
Journal of pediatric endocrinology & metabolism : JPEM.
18(2):111-23
[PMID] 15751600.
Grants
Feb 2023
ACTIVE
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Role: Principal Investigator
Funding: WORLDWIDE CLINICAL TRIALS
via RHYTHM PHARMACEUTICALS
Jan 2023
ACTIVE
An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients with Prader-Willi Syndrome
Role: Principal Investigator
Funding: PROTRIALS RESEARCH
via SOLENO THERAPEUTICS
Mar 2022
– Oct 2023
A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 Study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Receptor Pathway
Role: Principal Investigator
Funding: IQVIA Holdings
via RHYTHM PHARMACEUTICALS
Dec 2021
ACTIVE
A Phase 2a Evaluation of Psilocybin (TRP-8802) Administration in Concert with Psychotherapy to Decrease Hyperphagia in Patients with Overeating
Disorders
Role: Principal Investigator
Funding: TRYP THERAPEUTICS
Sep 2021
– Dec 2023
A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects with Hypothalamic Obesity
Role: Principal Investigator
Funding: ADVANCED CLINICAL LLC
via RHYTHM PHARMACEUTICALS
Feb 2021
ACTIVE
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients with Prader-Willi Syndrome, Followed by an Open Label Extension
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via HARMONY BIOSCIENCES
Jul 2020
ACTIVE
An Open-Label, Long-Term Safety Study to Evaluate the Safety and Tolerability of Pitolisant in Pediatric Patients with Prader-Willi Syndrome (PWS) who Participated in Study HBS-101-CL-003
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via HARMONY BIOSCIENCES
Mar 2020
ACTIVE
Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway
Role: Principal Investigator
Funding: ADVANCED CLINICAL LLC
via RHYTHM PHARMACEUTICALS
Mar 2020
– Mar 2023
Research Supportive Service Agreement
Role: Principal Investigator
Funding: TRYP THERAPEUTICS
Apr 2019
– Mar 2020
PATH for PWS – PATH Study Investigator
Role: Principal Investigator
Funding: FOU FOR PRADER-WILLI RESEARCH
Nov 2018
– Aug 2023
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) with Long Term Follow-Up: CARE-PWS
Role: Principal Investigator
Funding: LEVO THERAPEUTICS
Oct 2018
– Oct 2023
An Open-Label, Long-Term Safety Evaluation of Diazoxide Choline
Controlled-Release Tablet in Patients with Prader-Willi Syndrome
Role: Principal Investigator
Funding: SOLENO THERAPEUTICS
Jul 2018
– Jul 2023
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare
genetic disorders of obesity
Role: Principal Investigator
Funding: ADVANCED CLINICAL LLC
via RHYTHM PHARMACEUTICALS
Jun 2018
– Apr 2023
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients with Prader-Willi Syndrome
Role: Principal Investigator
Funding: SOLENO THERAPEUTICS
Dec 2017
– Dec 2022
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients with Prader-Willi syndrome (PWS)
Role: Principal Investigator
Funding: ORPHAN REACH
via GLWL RES
Jun 2017
– May 2019
Evaluating Factors that may affect the Efficacy of Intranasal Oxytocin Treatment in PWS
Role: Principal Investigator
Funding: FOU FOR PRADER-WILLI RESEARCH
Jun 2017
– May 2019
Phase 2 Study: Intranasal Oxytocin for Treatment of Infants and Children with Prader-Willi Syndrome in Nutritional Phase 1a
Role: Principal Investigator
Funding: PRADER-WILLI SYNDROME ASSO
Sep 2016
– Sep 2021
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Role: Principal Investigator
Funding: RHYTHM PHARMACEUTICALS
Jul 2015
– Jun 2020
Prader-Willi Syndrome Research Fund
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2015
– Dec 2020
T+?a Marie DeFelice Prader-Willi Syndrome Research Fund
Role: Principal Investigator
Funding: UF FOUNDATION
Dec 2014
– Dec 2017
Randomized, Double-Blind, Pacebo-Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects with Prader-Willi Syndrome to Evaluate Total Body Fat Mass, Food-related Behavior and Safety over 6 Months
Role: Principal Investigator
Funding: ZAFGEN
Nov 2014
– Nov 2017
A Phase 2 Randomized Double-Blind Placebo-controlled Pilot Study to Assess the Effects of RM-493 a Melanocortin 4 Receptor (MC4R) Agonist in Obese Subjects with Prader-Willi Syndrome (PWS) on Safety Weight Reduction and Food-Related Behaviors
Role: Principal Investigator
Funding: RHYTHM PHARMACEUTICALS
Nov 2014
– Nov 2017
A Phase 2, Randomized, Double-Blind Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor Agonist in Obese Subjects with Prader-Willi Syndrome on Safety, Weight Reduction, and Food-Related Behaviors
Role: Principal Investigator
Funding: RHYTHM PHARMACEUTICALS
Feb 2014
ACTIVE
214 OPERATION ACCOUNT
Role: Principal Investigator
Funding: 214 OPERATING ACCOUNT
Education
Master of Clinical Investigation
2003-2005
·
University of Florida
Pediatric Endocrinology Fellowship
2001-2004
·
University of Florida
Pediatric Residency
1998-2001
·
University of Florida
Medical Doctor
1994-1998
·
University of Florida
Bachelor of Science
1990-1994
·
Emory University
Master of Science
1990-1994
·
Emory University
Contact Details
Phones:
- Business:
- (352) 265-7337
Emails:
- Business:
- jlmiller@ufl.edu
Addresses:
- Business Mailing:
-
DEPARTMENT OF PEDIATRICS
PO BOX 100296
JENNIFER MILLER
GAINESVILLE FL 326100296 - Business Street:
-
PO Box 100296
GAINESVILLE FL 32610